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Abstract
Background: Resistance to anti-malarial drugs hampers control efforts and increases the risk of morbidity and mortality from
malaria. The efficacy of standard therapies for uncomplicated Plasmodium falciparum and Plasmodium vivax malaria was assessed
in Chumkiri, Kampot Province, Cambodia.
Methods: One hundred fifty-one subjects with uncomplicated falciparum malaria received directly observed therapy with 12
mg/kg artesunate (over three days) and 25 mg/kg mefloquine, up to a maximum dose of 600 mg artesunate/1,000 mg mefloquine.
One hundred nine subjects with uncomplicated vivax malaria received a total of 25 mg/kg chloroquine, up to a maximum dose
of 1,500 mg, over three days. Subjects were followed for 42 days or until recurrent parasitaemia was observed. For P. falciparum
infected subjects, PCR genotyping of msp1, msp2, and glurp was used to distinguish treatment failures from new infections.
Treatment failure rates at days 28 and 42 were analyzed using both per protocol and Kaplan-Meier survival analysis. Real Time
PCR was used to measure the copy number of the pfmdr1 gene and standard 48-hour isotopic hypoxanthine incorporation
assays were used to measure IC50 for anti-malarial drugs.
Results: Among P. falciparum infected subjects, 47.0% were still parasitemic on day 2 and 11.3% on day 3. The PCR corrected
treatment failure rates determined by survival analysis at 28 and 42 days were 13.1% and 18.8%, respectively. Treatment failure
was associated with increased pfmdr1 copy number, higher initial parasitaemia, higher mefloquine IC50, and longer time to
parasite clearance. One P. falciparum isolate, from a treatment failure, had markedly elevated IC50 for both mefloquine (130 nM)
and artesunate (6.7 nM). Among P. vivax infected subjects, 42.1% suffered recurrent P. vivax parasitaemia. None acquired new P.
falciparum infection.
Conclusion: The results suggest that artesunate-mefloquine combination therapy is beginning to fail in southern Cambodia and
that resistance is not confined to the provinces at the Thai-Cambodian border. It is unclear whether the treatment failures are
due solely to mefloquine resistance or to artesunate resistance as well. The findings of delayed clearance times and elevated
artesunate IC50 suggest that artesunate resistance may be emerging on a background of mefloquine resistance.
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Background
The spread of drug resistant Plasmodium falciparum has
complicated efforts to control malaria, and can lead to
unnecessary mortality if ineffective drugs remain the
standard of care after drug-resistant strains become estab-
lished [1,2]. In south-east Asia, resistance to multiple anti-
malarial drugs, including chloroquine, sulphadoxine-
pyrimethamine, quinine, and mefloquine is common [3].
In the face of this situation, many countries in the region
have adopted artemisinin combination therapies, includ-
ing artesunate-mefloquine and artemether-lumefantrine.
In both Thailand and Cambodia, rising failure rates for
mefloquine monotherapy led to introduction of artesu-
nate-mefloquine combination therapy in 1995 and 2000
[4,5], respectively. The combination was more effective
than mefloquine monotherapy. Introduction of artesu-
nate in combination with mefloquine, a drug against
which resistance is already common in the region [6] may
not protect against the development and spread of artesu-
nate resistance. Indeed, preliminary reports from both
sides of the Thai-Cambodian border have suggested that
resistance to the artesunate-mefloquine combination may
be emerging. In 2003, a regimen of 25 mg/kg mefloquine
in two divided doses on day 0, and 12 mg/kg oral artesu-
nate divided into two doses on day 0 and day 1, in Trat,
Thailand, along the Cambodian border, produced an ade-
quate clinical and parasitological response (ACPR) at day
28 in only 78.6% of 44 patients with uncomplicated P.
falciparum  malaria; at three other sites in Thailand the
same regimen had an efficacy of > 90% [4]. In 2002 in Pai-
lin, a Cambodian province bordering Trat, a similar regi-
men produced ACPR at 28 days in 85.7% of subjects [5];
in this study almost one third of patients received less
than 12 mg/kg artesunate and 20 mg/kg mefloquine,
because blister pack doses were administered according to
age rather than to weight. Nonetheless, the ACPR was >
90% at sites outside of Pailin where the same dosing
scheme was used. In 2004, using dosing based on weight
rather than age, the 42 day ACPR was 79.3% in Pailin [5].
Both the Thai and Cambodian studies used directly
observed therapy and the Cambodian study also used
PCR correction for re-infection [7]. These findings suggest
that resistance to artesunate-mefloquine may be emerging
at the Thai-Cambodian border.
Although the Thai-Cambodian border is frequently cited
as an epicenter for the emergence of anti-malarial drug
resistance, there is no reason to think that new anti-malar-
ial drug resistance genotypes are constrained to arise
there. Mefloquine resistance is common in many areas
outside the Thai-Cambodian border region, and artemisi-
nin has been used as monotherapy in the Greater Mekong
Area for hundreds of years. Four sites in Cambodia were
recently surveyed for the presence of P. falciparum strains
containing amplifications of the pfmdr1 gene, associated
with mefloquine resistance. The highest prevalence of
amplifications was found in Chumkiri, in Southern Cam-
bodia, rather than at the Thai border in Pailin (unpub-
lished data). In order to ask whether the high background
of pfmdr1 amplification might favor emergence of resist-
ance to artesunate-mefloquine, an in vivo efficacy study of
combined 12 mg/kg artesunate and 25 mg/kg in uncom-
plicated  P. falciparum malaria using the recommended
WHO protocol for in vivo anti-malarial efficacy studies
was conducted. In accordance with then current Ministry
of Health recommendations the maximum dose used was
600 mg artesunate, 1,000 mg mefloquine. The efficacy of
25 mg/kg chloroquine, maximum dose 1,500 mg, as
monotherapy for uncomplicated P. vivax malaria was
studied simultaneously.
Methods
Study site
The study was conducted between August 2006 and Feb-
ruary 2008 in Chumkiri District, Kampot Province, in
southern Cambodia. Chumkiri is located approximately
100 km SSW of Phnom Penh and 50 km west of the Viet-
namese border, at 10.7° latitude N, 104.3° longitude E.
Chumkiri town is located on a plain used for rice cultiva-
tion and surrounded by forested mountains. The climate
is tropical with a rainy season extending from May-June to
November. Malaria cases occur throughout the year, but
most cases occur during the rainy season. Plasmodium fal-
ciparum and Plasmodium vivax are present in roughly equal
proportion.
Study subjects
Subjects who presented to the Chumkiri Health Center
with uncomplicated mono-infection by P. falciparum or P.
vivax  were recruited. Inclusion criteria for P. falciparum
infected subjects were 1) uncomplicated P. falciparum
infection with parasitaemia between 1,000 and 100,000
parasites/mm3 as determined by counting parasites per
200 white blood cells or per 1,000 red blood cells in
Giemsa-stained thick or thin blood films and multiplying
by standard estimates of white and red blood cell counts,
5,000 wbc/mm3 and 4,000,000 rbc/mm3, 2) age ≥ 1 year,
3) axillary temperature ≥ 37.5°C or a history of fever in
the past 24 hours, and 4) negative urine pregnancy test for
women. Exclusion criteria were 1) any sign of severe or
complicated malaria according to World Health Organi-
zation criteria [8] 2) unwillingness to remain at clinic for
directly observed therapy or to return for follow-up visits,
3) mixed species Plasmodium infection, and 4) breastfeed-
ing. Inclusion and exclusion criteria for uncomplicated P.
vivax infection were identical except that the lower limit of
parasitaemia was 500 parasites/mm3.
Anti-malarial therapy and follow-up
Subjects with uncomplicated falciparum malaria received
a total dose of 12 mg/kg artesunate (MissionPharma,
Lynge, Denmark, 50 mg tablets) in three daily doses andMalaria Journal 2009, 8:10 http://www.malariajournal.com/content/8/1/10
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a total dose of 25 mg/kg mefloquine (PharmaDanica,
Lynge, Denmark 250 mg tablets) in two doses eight hours
apart, up to a maximum dose of 600 mg artesunate and
1,000 mg mefloquine. Subjects with uncomplicated vivax
malaria received a total dose of 25 mg/kg chloroquine
base (Nanjing Baijingyu Pharmaceutical Company, Ltd,
Nanjing, China, 150 mg tablets) given 10 mg/kg on day 0
and day 1, and 5 mg/kg on day 2, up to a maximum total
dose of 1,500 mg. All doses were directly observed. If the
patient vomited within one hour of receiving a dose, the
dose was repeated. The study physician evaluated each
subject and collected blood for malaria thick and thin film
examination on days 0,1,2,3,7,14,21,28,35, and 42, and
at any time when the subject reported to the clinic with
fever or other symptoms suggestive of malaria. Two
microscopists read all blood smears; a third reference
microscopist resolved any discrepancies. Patients with
recurrent P. falciparum parasitaemias received oral quinine
sulfate, 10 mg salt/kg three times daily, and tetracycline 1
g per day. Patients with new or recurrent P. vivax parasitae-
mia during the follow-up period received chloroquine as
above.
Parasite genotyping
For initial infections and recurrences with P. falciparum,
DNA isolation and characterization of allelic polymor-
phisms in the genes encoding MSP1, MSP2, and GLURP
by PCR were performed as described [9]. If any of the alle-
les from any of the three genes present in the sample from
the day of recurrence were not present in the Day 0 sam-
ple, then the recurrence of parasitaemia was ascribed to a
new infection rather than to treatment failure. The copy
number of the pfmdr1 gene was determined by Real Time
PCR (RT-PCR) as previously described [10]. In brief, a
multiplexed assay using primers and a FAM-TAMRA (6-
carboxyfluorescein 6-carboxy-tetra-methylrhodamine)
labeled probe specific for pfmdr1 [11] and primers and a
VIC-TAMRA (proprietary formula, ABI, Foster City, CA)
probe [12] specific for β-tubulin was carried out, so that
both genes could be assayed in the same reaction. The
probes were obtained from MWG Biotech (High Point,
NC) and the primers from Applied Biosystems (ABI, Fos-
ter City, CA). PCR reactions were performed on the Roto-
gene 6000 thermocycler (Corbett Life Science, New South
Wales, Australia). Each plate included a sample from the
control  P. falciparum strains 3D7 and Dd2, which are
known to have one and four pfmdr1 copies, respectively
[13,14]. Pfmdr1 copy number was calculated as follows:
copy number = (Eβ-tubulin)CT(β-tubulin)/(Epfmdr1)CT(pfmdr1),
where E and CT represent the efficiency and cycle thresh-
old of the respective targets. It was assumed that Eβ-tubulin
= 2; Epfmdr1 was then calculated using the CTpfmdr1 and CTβ-
tubulin values obtained with the 3D7 control. The results of
the assay were accepted if the Dd2 control had a calcu-
lated pfmdr1 copy number between 3.5 and 4.5.
In vitro drug resistance assay
The in vitro drug sensitivity of the P. falciparum isolates
was assessed by use of a classical isotopic 48-hour test
[15]. In brief, mefloquine and artesunate were obtained
from IMTSSA (Institut de Medicine Tropical, Service de
Santé des Armées, Marseille, France). Stock solutions of
mefloquine and artesunate were prepared in methanol
and further two-fold serial dilutions in distilled water
(Biosedra, France). The final concentrations ranged from
0.05 to 51.2 nM for artesunate and 1 to 1024 nM for
mefloquine. Two wells of a Falcon 96-well, flat-bottom
plate (ATGC, France) were coated with each drug concen-
tration, the plates were dried in a sterile cabinet, and were
stored at 4°C until use. Their suitability for in vitro testing
was monitored using reference strains of P. falciparum
with known drug sensitivities. Fresh blood samples were
washed three times with RPMI 1640 medium (GibcoTM,
Invitrogen Corporation, France) by centrifugation (800 g,
10 min, 4°C) and then tested directly without culture
adaptation. The infected erythrocytes (1.5% haematocrit,
0.1% – 1% parasitaemia) were suspended in complete
RPMI medium supplemented with 10% of decomple-
mented human AB+ serum (Biomedia, France), buffered
with 25 mM/l Hepes, 11 mM/l D-(+)-glucose 25 mM/l
NaHCO3, and containing [8-3H] hypoxanthine (0.5 μci/
well; Amersham Biosciences, France), and the mixture
(200 μl per well) was distributed into the 96-well test
plates pre-coated with anti-malarial drugs. Each plate
included two drug-free control wells and one control well
without parasites. The plates were incubated for 48 h at
37°C in a 5% CO2 atmosphere and the cells then lysed by
freeze-thawing. After collection on glass-fiber filter paper
using a cell harvester, the amount of [3H] hypoxanthine
incorporated into the parasites' nucleoprotein was deter-
mined using a Wallac MicroBeta Trilux counter (Perkin
Elmer, France). A log probit approximation was used to
determine the 50% inhibitory concentration (IC50),
defined as the concentration at which 50% of the incorpo-
ration of [3H] hypoxanthine was inhibited, as compared
with the drug-free control wells.
Statistical analysis
The primary outcome was recurrence of P. falciparum or P.
vivax  parasitaemia. Subjects who met World Health
Organization criteria for early treatment failure (parasitae-
mia on day 2 > on day 0, parasitaemia on day 3 > 25% of
parasitaemia on day 0, or fever and any parasitaemia on
day 3) [7] but who cleared their parasitaemia by day 7
were not given additional treatment and were not ana-
lyzed as treatment failures unless they subsequently suf-
fered recurrent parasitaemia. In the case of subjects with P.
falciparum malaria, the results of both per protocol and
Kaplan-Meier analysis are reported. In the per protocol
analysis the proportion of treatment failures was calcu-
lated by dividing the total number of subjects with recur-Malaria Journal 2009, 8:10 http://www.malariajournal.com/content/8/1/10
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rent parasitaemias (with or without PCR correction for re-
infection) by the number of subjects who either suffered
recurrent parasitaemia or completed the full 42 day fol-
low-up period. In the Kaplan-Meier analysis, subjects were
censored from the point at which they 1) were lost to fol-
low-up or 2) acquired a P. vivax infection. The proportion
of treatment failures for both day 28 and day 42 is
reported. In the case of subjects with uncomplicated P.
vivax malaria the analysis was identical, except that no
attempt was made to distinguish between recrudescence,
re-infection, and relapse from the liver. Subjects were con-
sidered to have cleared parasitaemia if there were at least
two sequential negative smears. The day on which the first
such negative smear was observed was defined as the day
of clearance. Because smears were not taken on days 4–6,
subjects with a reported clearance day 7 may actually have
cleared their parasitaemia on any day between day 4 and
7. All statistical analysis was performed with StataSE 8.0.
Results
In vivo efficacy
The baseline characteristics of the study subjects are
shown in Table 1. Between August 2006 and December
2007, 151 subjects with uncomplicated P. falciparum
malaria were enrolled. One subject withdrew before com-
pleting treatment. Of the 150 who completed treatment,
127 (84.7%) still had P. falciparum parasitaemia on day 1,
71 (52.7%) on day 2, and 17 (11.3%) on day 3. All sub-
jects were free of parasitaemia by day 7. Of these 150 sub-
jects, seven (4.7%) were lost to follow-up before
completing 42 days follow-up. Among the remaining 143
subjects, 31 (20.7%) developed recurrent P. falciparum
parasitaemia. None of the recurrent parasitaemias
occurred before day 14. Based on PCR genotyping for
MSP1, MSP2, and GLURP, 4 of these parasitaemias were
judged to be new infections and 27 to be recrudescences.
Of the 27 recrudescences, 24 were accompanied by fever
(axillary temperature ≥ 37.5°C) and were classified as late
clinical failures; the remaining 3 were classified as late par-
asitological failures. Four subjects met criteria for early
treatment failure[7], but cleared their parasitaemia by day
7 without additional treatment. Of these four, three suf-
fered recrudescences (two on day 21, one on day 28); one
remained aparasitemic from day 7 through the end of the
42 day follow-up and was not counted as a treatment fail-
ure. Eight subjects (5.3%) developed P. vivax parasitae-
mia, one on day 32 and seven on day 42. Figure 1 shows
the Kaplan-Meier survival curve for PCR-corrected artesu-
nate-mefloquine efficacy, throughout the follow-up
period. Table 2 shows failure rates at days 28 and 42, cal-
culated on both a per protocol and survival analysis basis,
with and without PCR correction for re-infection.
One hundred ten subjects with uncomplicated vivax
malaria were enrolled. One subject was withdrawn from
the study on day 1 when he was found to have a mixed P.
vivax/P. falciparum infection. Of the remaining 109 sub-
jects, 79 (72.5%) still had P. vivax parasitaemia on day 1,
5 (4.6%) on day 2, and 1 (0.9%) on day 3. All subjects
were free of parasitaemia by day 7. Two subjects were lost
to follow-up, at 28 and 25 days. Among the 107 subjects
who completed follow-up, 45 (42.1%) suffered recurrent
P. vivax parasitaemia; all recurrent parasitaemias occurred
between day 28 and day 42. No attempt was made to dis-
tinguish between recrudescence, relapse from the liver,
and re-infection. None of the P. vivax subjects acquired P.
falciparum infection during follow-up.
Predictors of treatment failure
For logistical reasons, it was possible to measure the IC50
for mefloquine and artesunate in samples from only 51 P.
falciparum subjects, 38 subjects who did not suffer a recru-
descence and 13 who did. Figure 2 shows the IC50 for
mefloquine and artesunate for each of these samples. The
mean mefloquine IC50 in subjects who suffered a recru-
descence was 34 nM (95% CI 10–57) higher than in those
who did not, 90 nM (95% CI 65–115 nM) versus 56 nM
(95% CI 45–67 nM). The mean artesunate IC50 was also
higher in subjects who suffered recrudescence, 1.7 nM
(95% CI 0.7–2.7 nM), than in those who did not, 1.2 nM
(95%CI 1.0–1.5 nM), but the difference was not statisti-
cally significant.
Amplification of the pfmdr1 gene has been associated with
mefloquine resistance [16]. Table 3 shows the mean
pfmdr1 copy number and the proportion of samples with
estimated copy number > 1.5 in the samples from day 0
and from the day of recrudescence. Samples from the day
Table 1: Study subject demographics and parasitaemia
Species Sex, male (%) Age, yrs (S.D.) Geometric Mean Parasitaemia, parasites/mm3 (5, 95 centiles)
P. falciparum 141/151
(93.4%)
27.1
(9.5)
5857
(1250, 43375)
P. vivax 97/109
(89.0%)
21.2
(6.7)
5427
(1000, 11000)Malaria Journal 2009, 8:10 http://www.malariajournal.com/content/8/1/10
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Table 2: Failure rates for uncomplicated falciparum malaria treated with mefloquine artesunate
Analysis PCR Correction Failure Rate (%)
Day 28 (95% CI)
Failure Rate (%)
Day 42 (95% CI)
Kaplan-Meier Yes 13.1
(8.5, 19.7)
18.8
(13.3, 26.2)
No 15.1
(10.2, 22.0)
21.4
(15.5, 29.0)
Per Protocol Yes 13.4
(7.8, 19.0)
19.4
(12.8, 26.0)
No 15.2
(9.4, 21.0)
21.7
(14.9, 28.4)
Mefloquine-artesunate survival curve Figure 1
Mefloquine-artesunate survival curve. Shown is the proportion of subjects remaining free of P. falciparum following treat-
ment with mefloquine artesunate. The point estimate (bold line) and 95% confidence intervals (dotted lines) were calculated by 
Kaplan-Meier survival analysis. Only PCR-confirmed treatment failures are included.
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0 parasitaemia in subjects who ultimately suffered a recru-
descence had a higher mean pfmdr1 copy number than
those from subjects who did not (2.7 versus 1.9, P =
0.003, t test). The relative risk for recrudescence in sub-
jects with pfmdr1 copy number > 1.5 was 3.5 (95% CI 1.4–
8.8). Recrudescent samples had a higher mean copy
number than the corresponding day 0 samples (3.5 versus
2.6, P = 0.0013, paired t test).
Table 4 shows the relationship between the day of clear-
ance, the risk of recrudescence, amplification of the
pfmdr1 gene, and the initial parasite density. Longer time
In vitro susceptibilities to mefloquine and artesunate Figure 2
In vitro susceptibilities to mefloquine and artesunate. Shown are the IC50 for mefloquine and artesunate for parasite 
samples from patients who did (black circles) or did not (white circles) suffer a PCR-confirmed treatment failure.
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Table 3: Relationship between pfmdr1 copy number and risk of recurrence
Recrudescence Number pfmdr1 Copy #
(95% CI) Day 0
Proportion with Copy # > 1.5
Day 0
pfmdr1 Copy #
(95% CI) Day Recur
Proportion with Copy # > 1.5
Day Recur
No 122 1.9
(1.7–2.2)
0.45 3.0*
(0.9–5.2)
0.75*
Yes 27 2.7
(2.1–3.2)
0.74 3.6
(2.9–4.3)
0.85
*Results from the 4 subjects with recurrent parasitaemia classified as re-infection by PCRMalaria Journal 2009, 8:10 http://www.malariajournal.com/content/8/1/10
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to parasite clearance was associated with greater risk of
subsequent recrudescence, a greater proportion of pfmdr1
amplification, and higher initial parasitaemia. Table 5
shows the results of multiple logistic regression analysis of
factors associated with risk of recrudescence; higher initial
parasitaemia, longer clearance time, and pfmdr1  copy
number were independently associated with higher risk of
recrudescence.
Discussion
An unexpectedly high failure rate for artesunate-meflo-
quine treatment of uncomplicated falciparum malaria
was found at a site in Cambodia far from the Thai-Cam-
bodian border, frequently considered a hot spot for the
emergence of anti-malarial drug resistance. The failure
rates at 28 and 42 days, calculated using Kaplan-Meier sur-
vival analysis and PCR correction for re-infection, were
13.1% (95% CI 8.5–19.7%) and 18.8% (95% CI 13.3–
26.2%), respectively. Although it was not possible to
measure circulating drug levels during therapy, all doses
were directly observed, and the drugs were obtained
through the Cambodian Ministry of Health from suppli-
ers following current Good Manufacturing Practices.
Thus, while it is formally possible that the unexpectedly
high failure rates are due to adulterated, defective, or
counterfeit anti-malarials, it seems unlikely. The study
used the then current maximum dose of mefloquine,
1,000 mg. It is possible that efficacy would have been
higher had we used a maximum of 1,250 or 1,500 mg. If
treatment failures were related to a low dose/weight of
mefloquine, it would have been expected that heavier
subjects would be at greater risk of failure. The mean
weight, however, of subjects who had an ACPR (50.6 kg;
95% CI 49.0, 52.3), was not significantly different from
those who did not (51.0 kg; 95% CI 47.8, 54.2); similarly
the mean administered mefloquine dose per kg did not
differ significantly between ACPR and failure (19.8 mg/kg
vs. 19.7 mg/kg, P = 0.85, t-test). The risk of failure was the
same in subjects < 40 kg, 40–50 kg, or > 50 kg, and in
regression analysis there was no relationship between
either weight or actual mefloquine dose per kg and time
to clearance or risk of recrudescence. It therefore seems
unlikely that increasing the maximum mefloquine dose
would have significantly changed the observed failure
rates.
It is possible that PCR correction in fact led to an underes-
timation of the failure rate. Malaria transmission is not
intense at this study site; most infections (> 80%) con-
tained only a single genotype (data not shown). None of
the 109 subjects enrolled with uncomplicated P. vivax
malaria and treated with chloroquine acquired new P. fal-
ciparum infection during the 42 day follow-up period, sug-
gesting that the P. falciparum attack rate is relatively low.
PCR genotyping may miss minor parasite populations
present on day 0 which may be selected during treatment,
thus incorrectly characterizing treatment failures as new
infections. That such selection occurred is suggested by
the observation (Table 3) that the mean pfmdr1  copy
number increased from day 0 to the day of recurrence,
even in the 4 cases classified by PCR as re-infection. If
these four cases in fact represent additional treatment fail-
ures, then the 28 and 42 day failure rates would be 15.1%
(95%CI 10.2–22.0%) and 21.4% (95% CI 15.5–29.0%),
respectively.
Use of non-study anti-malarial drugs during follow-up
might also lower the measured treatment failure rate.
Although subjects were instructed not to take anti-malar-
ial drugs during the follow-up period, except those pro-
vided as treatment for documented recurrences by the
study team, and although none reported having done so,
Table 4: Parasite clearance times
Day of Clearance* Number (%)
(95% CI)
Treatment Failure
Proportion
(95% CI)
pfmdr1 Copy # > 1.5
Proportion
(95% CI)
Day 0 Parasite Density (parasites/mm3)
Geometric Mean
(95% CI)
1 23 (15.3)
(9.5–21.2)
0.0
(0.0–0.13)
0.22
(0.05–0.39)
3099
(2049–4687)
2 56 (37.3)
(29.5–45.1)
0.16
(0.06–0.26)
0.52
(0.39–0.65)
5336
(4089–6964)
3 54 (36.0)
(28.2–43.8)
0.19
(0.09–0.29)
0.57
(0.44–0.70)
7741
(5887–10179)
7 17 (11.3)
(6.2–16.5)
0.47
(0.23–0.72)
0.59
(0.36–0.82)
8061
(4912–13230)
*Parasitaemia was considered to have cleared after two negative smears. The day on which the first of these two negative smears was observed was 
counted as the day of clearance.Malaria Journal 2009, 8:10 http://www.malariajournal.com/content/8/1/10
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we cannot exclude the possibility that some subjects may
have taken non-study anti-malarial drugs. Such unre-
corded treatment might have reduced the apparent treat-
ment failure rate. In that case the failure rates reported
herein would be an underestimate.
It is not clear whether the resistance observed here is due
entirely to resistance to mefloquine, or whether there is
also a contribution of resistance to artesunate. It is well
known that a 3 day regimen of artesunate monotherapy
for P. falciparum has a high risk of late recrudescence
[17,18]. It is possible that mefloquine resistance is effec-
tively converting the artesunate-mefloquine combina-
tion therapy used here into artesunate monotherapy.
Indeed, both the presence of amplification of the pfmdr1
gene and elevated mefloquine IC50 were predictive of
treatment failure. It may be that all the observed treat-
ment failures are due solely to mefloquine resistance.
There was, however, some evidence suggestive of resist-
ance to artesunate. First, pure mefloquine resistance
should not greatly affect the time to parasite clearance in
subjects treated with artesunate-mefloquine combina-
tion therapy. Trials of artesunate monotherapy [19,20]
and artesunate-mefloquine combination therapy [21]
have generally found more rapid parasite clearance than
found at this site. For example, in a study conducted in
2001 on the western border of Thailand [21], treatment
with the same artesunate-mefloquine regimen used here
produced parasite clearance by day 2 in 98.4% of
uncomplicated P. falciparum infections. Similarly, in a
study carried out in northern Lao in 2003 [22], the same
artesunate-mefloquine regimen cleared 98.1% of sub-
jects by day 2. Although clearance times with artesunate-
mefloquine may be slightly faster than with artesunate
monotherapy [19], even artesunate monotherapy is
expected to clear parasitaemia in > 90% of subjects by
day 2 [19,20]. In contrast, only 53% of subjects in the
current study treated with artesunate-mefloquine were
free of parasitaemia by day 2. Second, although the
artesunate IC50 values were not strongly predictive of
treatment failure, one sample with markedly elevated
IC50 for both artesunate (6.7 nM) and mefloquine (130
nM) was identified. It thus appears possible that, at this
study site, artesunate resistance is beginning to emerge
on a background of pre-existing mefloquine resistance. If
recent reports of declining efficacy of artesunate-meflo-
quine in Trat, Thailand [4], and Pailin, Cambodia [5],
near the Thai-Cambodian border similarly reflect early
emergence of artesunate resistance, then that resistance
may not be confined to a small focus on the Thai-Cam-
bodian border. Regardless of the specific target or mech-
anism of resistance, the failure rates observed here for
artesunate-mefloquine, if confirmed elsewhere, suggest
that it may be necessary to use a different partner drug in
artemisinin combination therapy in Cambodia.
Current Cambodian Ministry of Health treatment guide-
lines do not include primaquine treatment for vivax
malaria because of the difficulty in screening for G6PD
deficiency before treatment. It is not surprising that fre-
quent recurrent P. vivax parasitaemia by day 42 (45/110,
41.3%) was found. All of the recurrent parasitaemias
occurred after day 28 and all but 2 after day 35. Given the
late timing of the recurrences, the absence of radical treat-
ment to eliminate hypnozoites from the liver, and the lack
of blood chloroquine levels on the day of recurrence, it is
impossible to draw any conclusions about chloroquine
resistance. It is clear, however, that subjects with vivax
malaria treated with chloroquine alone are at substantial
risk of recurrent morbidity; further studies including pri-
maquine treatment and measurement of drug levels will
be required to determine whether chloroquine resistance,
reported elsewhere in south-east Asia, is a problem in
Cambodia.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
WOR participated in study design and data collection,
analyzed the data and drafted the manuscript; RS per-
formed the pfmdr1 copy number assays and performed
quality control on the data; TT examined and performed
follow-up of study subjects after treatment; PC partici-
pated in the in vitro drug resistance assays; PL partici-
pated in the in vitro drug resistance assays; SM
participated in study design; DS participated in study
design; FA oversaw the in vitro drug resistance and
pfmdr1  copy number assays and participated in data
analysis; CW conceived the study, participated in study
design, and performed quality control of data. All
authors contributed to the critical review of the manu-
script and agree to submission.
Table 5: Multiple logistic regression model of risk factors for 
recrudescence.
Risk factor Odds ratio* (95% CI) P value
Log parasite density 3.40 (1.12, 10.3) 0.031
Day of clearance 1.48 (1.13, 1.94) 0.004
Pfmdr1 copy number 1.92 (1.32, 2.79) 0.001
*This represents the increment in the odds ratio for recrudescence 
for each single unit increase in the risk factor, one log of parasitaemia 
density, one additional day for clearance, or one additional copy of 
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